Vincent Martin, a neurologist at the University of Cincinnati, has spent years listening to migraine patients describe the same frustrating pattern: their headaches flare up when a storm rolls in. Now, he and collaborators from Mount Sinai and pharmaceutical researchers have identified exactly which weather patterns trigger these attacks—and shown that a single medication can stop them.
The research matters because weather-triggered migraines affect millions of people, particularly across the Northeastern United States and Midwest. Yet until now, scientists struggled to pinpoint which specific atmospheric conditions caused the problem. Most studies looked at single variables like barometric pressure or humidity in isolation. This new investigation took a different approach, analyzing complex weather patterns as they actually occur in nature, combining multiple meteorological variables across seasons and regions.
Working with data from large Phase III clinical trials of the medication fremanezumab (brand name Ajovy), Martin's team reviewed thousands of daily headache diary entries from Northeast U.S. patients. They cross-referenced these entries against four years of meteorological data from the National Climatic Data Center, organizing the information into three-day windows to catch the lag between weather shifts and headache onset. Two patterns emerged as significant culprits. The first is an approaching cold front—a low-pressure system with precipitation—which can strike during any season. The second is the Bermuda High, a high-pressure system that dominates summer weather patterns across the eastern half of the United States.
"Weather is one of the most common triggers for attacks of migraine headache," Martin said. What made this investigation stand out was its granularity. As Al Peterlin, a meteorologist from Errex Inc., noted, "This is one of the first studies to more closely implicate frontal passage in the onset of headache."
But the most striking finding came from the medication data. Patients who received at least six months of treatment with fremanezumab showed a significantly reduced rate of new-onset headaches compared with those on placebo—across all weather patterns, including the high-risk conditions identified in the study. Fred Cohen, a co-investigator at Mount Sinai, described witnessing this effect firsthand: "We saw the weather and headache relationship wiped out with the use of this medication. We started to notice its effectiveness as early as one month after the start of the medication."
For millions of migraine sufferers who check weather forecasts the way others check horoscopes, this represents a genuine breakthrough. It offers the first concrete evidence that a preventive medication can interrupt the biological cascade triggered by atmospheric change. The research was presented at the American Headache Society Annual Scientific Meeting in June.
Brinder Vij, lead author of the study, framed the significance plainly: "This is one of the first studies to suggest that a preventive medication might reduce the likelihood of a weather-associated headache." That clarity—knowing not just what causes the problem, but having a tool to prevent it—transforms migraine management from reactive crisis control into genuine prevention.